The clinical evaluation committee in a large multicenter phase 3 trial of drotrecogin alfa (activated) in patients with severe sepsis (PROWESS): role, methodology, and results.
about
Human recombinant activated protein C for severe sepsisHuman recombinant protein C for severe sepsis and septic shock in adult and paediatric patientsHuman recombinant activated protein C for severe sepsisHuman recombinant activated protein C for severe sepsisDelaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortalityBench-to-bedside review: antimicrobial utilization strategies aimed at preventing the emergence of bacterial resistance in the intensive care unit.Drotrecogin alfa (activated) in severe sepsis: a systematic review and new cost-effectiveness analysisPseudomonas aeruginosa bloodstream infection: importance of appropriate initial antimicrobial treatmentEmpiric combination antibiotic therapy is associated with improved outcome against sepsis due to Gram-negative bacteria: a retrospective analysisAppraising contemporary strategies to combat multidrug resistant gram-negative bacterial infections--proceedings and data from the Gram-Negative Resistance Summit.An institutional perspective on the impact of recent antibiotic exposure on length of stay and hospital costs for patients with gram-negative sepsisActivated protein C in sepsis.Comparison of mechanisms after post-hoc analyses of the drotrecogin alfa (activated) and antithrombin III trials in severe sepsis.Drotrecogin alfa: a role in emergency department treatment of severe sepsis?Safety of drotrecogin alfa (activated) in the treatment of patients with severe sepsis.Underlying disorders and their impact on the host response to infection.Coagulopathy and the role of recombinant human activated protein C in sepsis and following polytrauma.The effect of drotrecogin alfa (activated) on long-term survival after severe sepsis.A clinical evaluation committee assessment of recombinant human tissue factor pathway inhibitor (tifacogin) in patients with severe community-acquired pneumoniaDesign and rationale of the PREVENT III clinical trial: edifoligide for the prevention of infrainguinal vein graft failureSeptic shock attributed to Candida infection: importance of empiric therapy and source control.Positive effect of septimeb™ on mortality rate in severe sepsis: a novel non antibiotic strategy.Predictors of hospital mortality for patients with severe sepsis treated with Drotrecogin alfa (activated).Recombinant human activated protein C as a therapy for severe sepsis: lessons learned?
P2860
Q24201123-80320EAF-49B8-449E-A5B9-B6AA0A861F1FQ24202128-11163391-512F-4877-923D-04760D51C1B0Q24235181-E5CEF57A-104B-4C65-998A-BBEB7D75EFB5Q24242859-56A8CD16-38A3-40AD-8997-A609662148B7Q24530412-CF34E89D-E1C8-4002-A231-EE9A2071BF93Q24813204-78A31C67-3641-401B-A8A5-3E1375EFE1DDQ33288889-5B433AB6-F750-4051-A515-BBB2133DAB6CQ33722082-00BBB0C1-F9FE-4D0F-9D2A-B03BD6C0BFD7Q33826400-116918D9-93C6-4B30-9D69-316CF56117A4Q34003193-7BF715B5-9161-42C9-93F4-0E7DA395B44EQ34194422-02B694B3-3355-439A-A09F-1D8481CC4522Q35751716-65BCEDF9-5472-4730-A5F4-0CE3885CE233Q35794980-D3F40F00-37C4-46A0-BE00-FA9F9D4A3663Q35850483-37098E45-0C57-4E3B-AB6A-F252AB312B5AQ35925664-5C2BD672-1FF2-49B1-AA20-08947A6049EFQ36291747-0BE2307B-38DA-4E30-A430-0587BE6D0710Q36349735-D5CA8FDC-A12F-4A7E-AA21-A01BB53E9C38Q36467579-1F44F039-2645-4D6E-A264-0E702F176CA8Q37210059-AA82D38C-0C54-4140-8DFF-5ADB84A7E5E3Q38330884-275EF11E-8C63-40F5-94F6-B075FCF24EF7Q40026437-CFB6E9AF-5141-4227-80A7-62D4C66915EFQ43007704-4F65D033-1D66-4F6E-8B13-7E5313135063Q46378350-6EA2A057-BF80-4ACD-9368-47585354E730Q50992726-4DE987C6-C229-4B76-852F-C6DA02E12723
P2860
The clinical evaluation committee in a large multicenter phase 3 trial of drotrecogin alfa (activated) in patients with severe sepsis (PROWESS): role, methodology, and results.
description
2003 nî lūn-bûn
@nan
2003 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
The clinical evaluation commit ...... ole, methodology, and results.
@ast
The clinical evaluation commit ...... ole, methodology, and results.
@en
type
label
The clinical evaluation commit ...... ole, methodology, and results.
@ast
The clinical evaluation commit ...... ole, methodology, and results.
@en
prefLabel
The clinical evaluation commit ...... ole, methodology, and results.
@ast
The clinical evaluation commit ...... ole, methodology, and results.
@en
P2093
P921
P1476
The clinical evaluation commit ...... ole, methodology, and results.
@en
P2093
Barbara G Utterback
Becky M Bates
Darell Heiselman
Dennis Maki
Gary E Garber
Gary T Kinasewitz
Howard Levy
Jean-François Dhainaut
Jean-Pierre Sollet
Peter Morris
P304
P356
10.1097/01.CCM.0000085089.88077.AF
P407
P577
2003-09-01T00:00:00Z